Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.
Stock price when the opinion was issued
As of Jul 30, 2026. Market Open.
Spun off from Merck two years, but has been sitting in the penalty box. Pays a 5.5% dividend at 5x earnings.
It has no growth.
Build your watch list
Sign in to track investmentsyou care about
Black Swan Dexteritas
Stockchase Premium
Stockchase
CNBC
Kingwest & Company
Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.